Metsera, Inc. (NASDAQ:MTSR – Get Free Report)’s share price was down 9.4% on Thursday . The stock traded as low as $23.19 and last traded at $23.36. Approximately 202,354 shares traded hands during trading, a decline of 64% from the average daily volume of 561,206 shares. The stock had previously closed at $25.78.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on MTSR shares. Cantor Fitzgerald started coverage on shares of Metsera in a research note on Tuesday, February 25th. They set an “overweight” rating on the stock. Evercore ISI started coverage on shares of Metsera in a research note on Tuesday, February 25th. They set an “outperform” rating on the stock. Bank of America started coverage on shares of Metsera in a research note on Tuesday, February 25th. They set a “buy” rating and a $38.00 price target on the stock. Finally, Guggenheim started coverage on shares of Metsera in a research note on Tuesday, February 25th. They set a “buy” rating and a $56.00 price target on the stock.
Get Our Latest Analysis on MTSR
Metsera Price Performance
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
- Five stocks we like better than Metsera
- What is a support level?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Plot Fibonacci Price Inflection Levels
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
- What Does Downgrade Mean in Investing?
- Why Costco Stock Is Poised to Hit $1,000 Again Soon
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
